6533b832fe1ef96bd129af82

RESEARCH PRODUCT

Nonalcoholic fatty liver and metabolic syndrome in Italy: Results from a multicentric study of the Italian Arteriosclerosis society

M SoresiD NotoAb CefalùS MartiniGb VignaM FondaE ManzatoL CattinR FellinMr AvernaA Notarbartolo Metabolic Syndrome Study GroupElmo MannarinoMatteo Pirro

subject

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismNonalcoholic fatty liverSex FactorSettore MED/13 - EndocrinologiaBody Mass IndexEndocrinologyNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseAtherosclerosis; Metabolic Syndrome X; Sex Factors; Humans; Lipids; Aged; Fatty Liver; Non-alcoholic Fatty Liver Disease; Body Mass Index; Italy; Logistic Models; Risk Factors; Liver; Middle Aged; Female; MaleUltrasonographyMulticentric studyMetabolic Syndrome XFatty liverGeneral MedicineArteriosclerosisLipidMiddle AgedLipidsMetabolic syndromeDiabetes and MetabolismItalyLiverAtherosclerosiFemaleHumanmedicine.medical_specialtyLogistic ModelNonalcoholic fatty liver Metabolic syndrome Lipids Multicentric studyInsulin resistanceSex FactorsDiabetes mellitusInternal medicinemedicineInternal MedicineHumansLipids; Metabolic syndrome; Multicentric study; Nonalcoholic fatty liver; Aged; Body Mass Index; Fatty Liver; Female; Humans; Italy; Lipids; Liver; Logistic Models; Male; Metabolic Syndrome X; Middle Aged; Non-alcoholic Fatty Liver Disease; Risk Factors; Sex Factors; Atherosclerosis; Endocrinology; Internal Medicine; Endocrinology Diabetes and MetabolismAgedbusiness.industryRisk Factornutritional and metabolic diseasesAmbientalemedicine.diseaseAtherosclerosisFatty LiverEndocrinologyLogistic ModelsMetabolic syndromeSteatosisbusinessBody mass index

description

Nonalcoholic fatty liver disease (NAFLD) is associated with all the components of metabolic syndrome (MS) and might to be considered an additional component of MS itself. The Italian Society for the Study of Atherosclerosis (SISA) in 2005 started a research project aimed to study the NAFLD, using ultrasound (US), in nondiabetic MS subjects matching at least one of the ATP III criteria for HDL-C or triglycerides [TG]. Prevalence of US-NAFLD and its associated risk factors and prevalence of hypertransaminasemia and its possible determinants were evaluated. NAFLD prevalence was 0.78. Men with steatosis compared to men without steatosis were younger (P < 0.05) with higher TG (P < 0.03), homeostasis model assessment insulin resistance (HOMA-R) (P < 0.003), and visceral fat thickness (VFT) (P < 0.0001). Women with steatosis showed higher TG (P < 0.05), HOMA-R (P < 0.04), VFT (P < 0.0001), and lower age (P < 0.05). At multivariate analyses, VFT (P < 0.0001), HOMA-R (P < 0.02), and TG/HDL (P < 0.05) were associated with severity of NAFLD. Age (P < 0.05), LogTG (P < 0.005), and VFT (P < 0.01) were associated with higher ALT. The US prevalence of steatosis in this study (0.78) is the highest reported in patients with MS. Considering the exclusion of severe obese and diabetic patients and the recruitment criteria, this finding highlights the prominent role played by the alterations of lipid metabolism in the pathogenesis of NAFLD. © 2012 Springer-Verlag.

yearjournalcountryeditionlanguage
2013-01-01
10.1007/s00592-012-0406-1http://hdl.handle.net/11392/2353715